Hologic Inc (HOLX) reports a 1% revenue increase with robust diagnostics performance, while facing headwinds in breast health ...

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat ...

Q1 2025 Management View CEO Steve MacMillan announced Q1 2025 revenue of $1.022 billion, reflecting a 1% increase on a constant currency basis, aligned with the company’s guidance. Non-GAAP EPS ...

Hologic Inc (NASDAQ:HOLX). reported its financial results for the first quarter of fiscal year 2025, showing a slight beat in earnings per share (EPS) but falling short on revenue expectations. The ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

While reporting its results for the first quarter, Hologic, Inc. (HOLX) revised its outlook for the full year 2025. Looking forward ...

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter profit of $201 million. On a per-share basis, the Marlborough, Massachusetts-based ...

The stock's rise snapped a three-day losing streak.

Hologic (NASDAQ:HOLX – Get Free Report) will likely be issuing its quarterly earnings data after the market closes on ...